Probiotics for Reduction of Infections With Clostridium Difficile in Critically Ill Patients (ProbiEnt)

Probiotics for Reduction of Colonisation With Clostridium Difficile in Antibiotic Treated Intensive Care Patients

Symptoms of Clostridium difficile infection is almost always induced as a complication to the use of antibiotics. Most ICU patients are given antibiotics.

Probiotics has the ability to improve conditions in the gut and it has been shown in some smaller studies that overgrowth of C. difficile can be reduced or prevented.

In this study the intention is to show with sufficient statistical power that a mixture of two otherwise well studied probiotic strains reduces or prevents the incidence of emerging colonisation with C. difficile in critical ill patients on antibiotics.

Half of the patients will be given a mixture of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v twice daily and the rest a placebo mixture.

Rectal swabs or faeces will be analysed for C.difficile and its toxins and the incidence of new cases will be compared for the two groups.

White blood cells (WBC´s), C reactive protein (CRP), lactate, urea, and creatinine will be followed daily as well as antibiotics, corticosteroids and all acid reducing medication.

Nutrition, enteral and total, and bowel habits will be recorded.

Study Overview

• Status: Terminated
• Conditions: Clostridium Difficile Colonisation; Impact of Enteral Probiotics on Certain Lab Parameters
• Intervention / Treatment: Dietary supplement: L. plantarum 299 and L. plantarum 299v (+maltodextrin); Other: Maltodextrin

Detailed Description

Infections with Clostridium difficile is considered to be the most frequent health care associated bacterial infection. Almost all cases are connected to the use of antibiotics.

The spectra of symptoms of infection reaches from loose stools to sepsis and death. It is estimated that about 5% of the population are carriers without symptoms.

Elderly people are more likely to be diagnosed with C. difficile infections and as about 50 % of ICU admissions (at least in Sweden) are patients aged 64 years or older C. difficile is also an ICU issue.

Probiotic bacteria given to antibiotic treated patients results in fever cases of infection with C. difficile as we and others have shown in some small studies. Due to a low statistical power in our former study this multicentre study is calculated to be large enough to fulfil statistical requirements.

Adult patients with an expected length of stay in intensive care for three days or more can be included.

Primary objective is to find emerging cases of colonisation with C. difficile and consequent symptoms of infection such as diarrhoea.

Cultures and toxin analyses will be taken at inclusion and every second day till day 13 and then every third or fourth day depending on length of ICU stay. Positive cases will be given antibiotics according to normal routines.

No other cultures are collected per protocol but all cultures will be recorded and results will be analysed in order to find any connection between treatment and reduction of secondary infections.

In our earlier small study we found an improved and normalised gut barrier function for those patients that were given probiotic bacteria compared to a worsened, scattered pattern for the placebo group. This is probably why we found that inflammatory parameters improved for the probiotics group while those parameters remained elevated for the control patients. The same goes for creatinine, urea and lactate. This is why we will record those parameters together with blood gas analyses in this expanded study.

Antibiotics and medication with corticosteroids, proton pump inhibitors or other acid reducing preparations, All nutritive prescriptions (enteral formulas and IV solutions as well as medical preparations containing glucose or fat) will be recorded and compared to actually given nutrients.

Bowel movements frequency and consistency will be recorded and compared between groups.

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Helsingborg, Sweden, SE 251 87
    • Intensive Care Unit, Helsingborg Hospital
  • Kristianstad, Sweden, SE 291 85
    • Intensive Care Unit, Kristianstad Central hospital
  • Lund, Sweden, SE 22185
    • Lund University Hospital
  • Umeå, Sweden, SE-901 85
    • Dept of Anesthesia & Intensive Care, University Hospital of Norrland

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Anticipated need for intensive care 3 days or longer
• Patients condition allowing enteral nutrition to be started within 24 h from ICU admission
• Antibiotics on-going or planned

Exclusion Criteria:

• Known positive test for Clostridium difficile within the last week
• Known ulcers in the mouth, oropharynx, esophagus and stomach
• Known immune deficiencies
• Enteral nutrition contra indicated
• Pancreatitis as admission diagnosis at the hospital or at the ICU
• ICU admission earlier during this period of illness Patient being moribund

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Probiotics; Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups	Dietary supplement: L. plantarum 299 and L. plantarum 299v (+maltodextrin); A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.; Other Names: Maltodextrin; Lactobacillus plantarum 299; Lactobacillus plantarum 299v
PLACEBO_COMPARATOR: Control; Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups	Other: Maltodextrin; A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Differences in emerging cases of Clostridium difficile	Emerging cases of Clostridium difficile, identified as positive cultures and/or toxin tests	Throughout the ICU stay, expected mean LOS 10 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
White blood cells	Samples taken at admission or inclusion and then daily	Throughout the ICU , expected mean LOS 10 days
C Reactive Protein	Samples taken at admission or inclusion and then daily	Throughout the ICU , expected mean LOS 10 days
Creatinine	Samples taken at admission or inclusion and then daily	Throughout the ICU , expected mean LOS 10 days
Urea	Samples taken at admission or inclusion and then daily	Throughout the ICU , expected mean LOS 10 days
Lactate	Samples taken at admission or inclusion and then daily	Throughout the ICU , expected mean LOS 10 days
Ventilator days	Records are held for how long the patients require mechanical ventilation	Throughout the ICU stay, expected mean LOS 10 days
Length of stay ICU	Length of stay is recorded for the ICU as well as for the Hospital stay	Length of ICU stay, about 10 days in accordance with a prior similar study
Length of Hospital stay	Length of stay is recorded for the Hospital as well as for the ICU stay	Within six months from date of ICU admission
Survival	For participating patients the status of survival or non survival at days 28 and 180 (six months) will be recorded	Six months
Diarrhea and obstipation	As ICU patients tend to display diarrhea as well as obstipation the frequency and consistency of stools will be recorded. Probiotics are anticipated to stabilise bowel function	Throughout the ICU stay, expected mean LOS 10 days

Collaborators and Investigators

• Sponsor: Region Skane
• Collaborators: Lund University
• Investigators: Principal Investigator: Bengt Klarin, MD, PhD, Lund University, Lund, Sweden

Publications and helpful links

General Publications

• Klarin B, Wullt M, Palmquist I, Molin G, Larsson A, Jeppsson B. Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol Scand. 2008 Sep;52(8):1096-102. doi: 10.1111/j.1399-6576.2008.01748.x.

Helpful Links

• Producers of the study products

Study record dates

Study Major Dates

• Study Start: June 1, 2012
• Primary Completion (ACTUAL): June 1, 2017
• Study Completion (ACTUAL): October 1, 2017

Study Registration Dates

• First Submitted: August 28, 2012
• First Submitted That Met QC Criteria: September 13, 2012
• First Posted (ESTIMATE): September 19, 2012

Study Record Updates

• Last Update Posted (ACTUAL): October 5, 2017
• Last Update Submitted That Met QC Criteria: October 3, 2017
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Keywords: Clostridium difficile; Lactate; CRP; Urea; Creatinine; WBC
• Additional Relevant MeSH Terms: Infections; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Clostridium Infections
• Other Study ID Numbers: ProENT11